ASP 0819Alternative Names: ASP0819
Latest Information Update: 02 Feb 2017
At a glance
- Originator Astellas Pharma
- Mechanism of Action Calcium-activated potassium channel openers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Fibromyalgia
Most Recent Events
- 31 Jan 2017 Phase-II clinical trials in Fibromyalgia in USA (PO) (Astellas Pharma pipeline, January 2017)
- 31 Oct 2015 Phase-I clinical trials in Fibromyalgia (PO)